Investigating protective T-cell immunity against infectious diseases using OncoPept Platform Technology
Natural immunity protects us from many pathogenic organisms during our lifetime. However, immune evasion strategies by infectious organisms, attenuation of robust immunity with age, and immune diseases that make us immune compromised can cause severe morbidity and mortality, evident from the recent coronavirus pandemic that has brought the world to a standstill. Understanding how the host immune interacts with the disease-causing organisms to develop protective immunity shapes the development of new strategies to fight infectious diseases. We have leveraged the technological advancements in the field of computational biology, genomics and proteomics to create the OncoPept platform that analyzes host immune responses to discover various aspects of protective immunity and how best to modulate them to gain control over the pathogen.
In this webinar, Dr. Amit Chaudhuri, VP R&D, MedGenome, will provide an overview of the OncoPept Platform Technology has enabled the identification of robust CD8 T-cell activating epitopes from SARS-CoV-2. I will briefly touch upon the utilities of T-cell epitopes in therapy and diagnostics.
Dr. Amitabha Chaudhuri
Vice President, R & D, MedGenome Inc.
Dr. Amitabha Chaudhuri brings over two decades of experience in discovering and validating novel targets and biomarkers of diseases, most extensively in oncology. Through his leadership, MedGenome has built its unique solutions to address challenges facing the IO field. He is actively involved in IO research in India in diseases such as Head & Neck cancer and familial colorectal cancer with a goal to target these diseases using cancer vaccines and combination therapy. He is also driving new research in the areas of autoimmunity and liver diseases at MedGenome.